PET-Based Volumetric Biomarkers for Risk Stratification of Non-Small Cell Lung Cancer Patients
Despite the recent advances in lung cancer biology, molecular pathology, and treatment, this malignancy remains the leading cause of cancer-related death worldwide and non-small cell lung cancer (NSCLC) is the most common form found at diagnosis. Accurate staging of the disease is a fundamental prog...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-01-01
|
| Series: | Diagnostics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-4418/11/2/210 |
| _version_ | 1797417554020401152 |
|---|---|
| author | Sara Pellegrino Rosa Fonti Alessandro Pulcrano Silvana Del Vecchio |
| author_facet | Sara Pellegrino Rosa Fonti Alessandro Pulcrano Silvana Del Vecchio |
| author_sort | Sara Pellegrino |
| collection | DOAJ |
| description | Despite the recent advances in lung cancer biology, molecular pathology, and treatment, this malignancy remains the leading cause of cancer-related death worldwide and non-small cell lung cancer (NSCLC) is the most common form found at diagnosis. Accurate staging of the disease is a fundamental prognostic factor that correctly predicts progression-free (PFS) and overall survival (OS) of NSCLC patients. However, outcome of patients within each TNM staging group can change widely highlighting the need to identify additional prognostic biomarkers to better stratify patients on the basis of risk. 18F-FDG PET/CT plays an essential role in staging, evaluation of treatment response, and tumoral target delineation in NSCLC patients. Moreover, a number of studies showed the prognostic role of imaging parameters derived from PET images, such as metabolic tumor volume (MTV) and total lesion glycolysis (TLG). These parameters represent three-dimensional PET-based measurements providing information on both tumor volume and metabolic activity and previous studies reported their ability to predict OS and PFS of NSCLC patients. This review will primarily focus on the studies that showed the prognostic and predictive role of MTV and TLG in NSCLC patients, addressing also their potential utility in the new era of immunotherapy of NSCLC. |
| first_indexed | 2024-03-09T06:20:24Z |
| format | Article |
| id | doaj.art-08db2a91453c42d390adf5457449043f |
| institution | Directory Open Access Journal |
| issn | 2075-4418 |
| language | English |
| last_indexed | 2024-03-09T06:20:24Z |
| publishDate | 2021-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Diagnostics |
| spelling | doaj.art-08db2a91453c42d390adf5457449043f2023-12-03T11:46:52ZengMDPI AGDiagnostics2075-44182021-01-0111221010.3390/diagnostics11020210PET-Based Volumetric Biomarkers for Risk Stratification of Non-Small Cell Lung Cancer PatientsSara Pellegrino0Rosa Fonti1Alessandro Pulcrano2Silvana Del Vecchio3Department of Advanced Biomedical Sciences, University “Federico II”, 80131 Naples, ItalyInstitute of Biostructures and Bioimages, National Research Council, 80145 Naples, ItalyDepartment of Advanced Biomedical Sciences, University “Federico II”, 80131 Naples, ItalyDepartment of Advanced Biomedical Sciences, University “Federico II”, 80131 Naples, ItalyDespite the recent advances in lung cancer biology, molecular pathology, and treatment, this malignancy remains the leading cause of cancer-related death worldwide and non-small cell lung cancer (NSCLC) is the most common form found at diagnosis. Accurate staging of the disease is a fundamental prognostic factor that correctly predicts progression-free (PFS) and overall survival (OS) of NSCLC patients. However, outcome of patients within each TNM staging group can change widely highlighting the need to identify additional prognostic biomarkers to better stratify patients on the basis of risk. 18F-FDG PET/CT plays an essential role in staging, evaluation of treatment response, and tumoral target delineation in NSCLC patients. Moreover, a number of studies showed the prognostic role of imaging parameters derived from PET images, such as metabolic tumor volume (MTV) and total lesion glycolysis (TLG). These parameters represent three-dimensional PET-based measurements providing information on both tumor volume and metabolic activity and previous studies reported their ability to predict OS and PFS of NSCLC patients. This review will primarily focus on the studies that showed the prognostic and predictive role of MTV and TLG in NSCLC patients, addressing also their potential utility in the new era of immunotherapy of NSCLC.https://www.mdpi.com/2075-4418/11/2/21018F-FDG PET/CTnon-small cell lung cancermetabolic tumor volumetotal lesion glycolysisprognosisimmunotherapy |
| spellingShingle | Sara Pellegrino Rosa Fonti Alessandro Pulcrano Silvana Del Vecchio PET-Based Volumetric Biomarkers for Risk Stratification of Non-Small Cell Lung Cancer Patients Diagnostics 18F-FDG PET/CT non-small cell lung cancer metabolic tumor volume total lesion glycolysis prognosis immunotherapy |
| title | PET-Based Volumetric Biomarkers for Risk Stratification of Non-Small Cell Lung Cancer Patients |
| title_full | PET-Based Volumetric Biomarkers for Risk Stratification of Non-Small Cell Lung Cancer Patients |
| title_fullStr | PET-Based Volumetric Biomarkers for Risk Stratification of Non-Small Cell Lung Cancer Patients |
| title_full_unstemmed | PET-Based Volumetric Biomarkers for Risk Stratification of Non-Small Cell Lung Cancer Patients |
| title_short | PET-Based Volumetric Biomarkers for Risk Stratification of Non-Small Cell Lung Cancer Patients |
| title_sort | pet based volumetric biomarkers for risk stratification of non small cell lung cancer patients |
| topic | 18F-FDG PET/CT non-small cell lung cancer metabolic tumor volume total lesion glycolysis prognosis immunotherapy |
| url | https://www.mdpi.com/2075-4418/11/2/210 |
| work_keys_str_mv | AT sarapellegrino petbasedvolumetricbiomarkersforriskstratificationofnonsmallcelllungcancerpatients AT rosafonti petbasedvolumetricbiomarkersforriskstratificationofnonsmallcelllungcancerpatients AT alessandropulcrano petbasedvolumetricbiomarkersforriskstratificationofnonsmallcelllungcancerpatients AT silvanadelvecchio petbasedvolumetricbiomarkersforriskstratificationofnonsmallcelllungcancerpatients |